Richard Pfenniger - Opko Health Independent Director
OPK Stock | 458.50 13.50 2.86% |
Director
Mr. Richard C. Pfenniger, Jr., serves as Independent Director of the Company. Mr. Pfenniger served as Interim CEO of Vein Clinics of America, Inc., a privately held company that specializes in the treatment of vein disease, from May 2014 to February 2015 and as Interim CEO of IntegraMed America, Inc., a privately held company that manages outpatient fertility medical centers, from January 2013 to June 2013. He served as Chief Executive Officer and President for Continucare Corporationrationration, a provider of primary care physician and practice management services, from 2003 until 2011, and served as Chairman of the Board of Directors of Continucare Corporation from 2002 until 2011. Previously, Mr. Pfenniger served as the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc. from 1997 through June 2003. Prior to joining Whitman, he served as the Chief Operating Officer of IVAX from 1994 to 1997, and, from 1989 to 1994, he served as the Senior Vice PresidentLegal Affairs and General Counsel of IVAX Corporationrationration. Prior thereto he was engaged in the private practice of law. Mr. Pfenniger currently serves as a director of GP Strategies Corporation, a corporate education and training company, TransEnterix, Inc., a medical device company, BioCardia, Inc., clinicalstage regenerative medicine company developing novel therapeutics for cardiovascular diseases, and IntegraMed America, Inc., a specialty healthcare services company offering products and services to patients and providers in the fertility and vein care segments of the health industry. He also serves as the Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. Mr. Pfenniger previously served as a director of Vein Clinics of America and Wright Investors Services Holdings, Inc., an investment management and financial advisory firm. since 2008.
Age | 62 |
Tenure | 16 years |
Phone | 305 575 4100 |
Web | https://www.opko.com |
Opko Health Management Efficiency
The company has return on total asset (ROA) of (0.0659) % which means that it has lost $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1867) %, meaning that it generated substantial loss on money invested by shareholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
JeanMichel Halfon | Teva Pharmaceutical Industries | 67 | |
Noit Levi | Tower Semiconductor | N/A | |
Roberto Mignone | Teva Pharmaceutical Industries | 47 | |
Yocheved Dvir | Nice | 66 | |
Joe Cowan | Nice | 66 | |
Dov Ninveh | Elbit Systems | 71 | |
Jean Halfon | Teva Pharmaceutical Industries | 62 | |
Richard Lerner | Teva Pharmaceutical Industries | 76 | |
Ory Slonim | Teva Pharmaceutical Industries | 73 | |
Zehava Simon | Nice | 60 | |
Galia Maor | Teva Pharmaceutical Industries | 73 | |
Kalman Kaufman | Tower Semiconductor | 72 | |
Roger Abravanel | Teva Pharmaceutical Industries | 71 | |
Gabrielle Sulzberger | Teva Pharmaceutical Industries | 56 | |
Tuvia Shoham | Kamada | 70 | |
Dan Propper | Teva Pharmaceutical Industries | 73 | |
Shmuel Rubinstein | Kamada | 78 | |
Jonathan Hahn | Kamada | 32 | |
Moshe Many | Teva Pharmaceutical Industries | 85 | |
Sagi Kabla | Tower Semiconductor | 38 | |
Dalia Rabin | Elbit Systems | 66 |
Management Performance
Return On Equity | -0.19 | |||
Return On Asset | -0.0659 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
Arie Gutman, Pres API | ||
Richard Lerner, Independent Director | ||
Dmitry Kolosov, Independent Director | ||
Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
Elias MD, Pres Chairman | ||
Richard Pfenniger, Independent Director | ||
Philip Frost, Chairman of the Board, CEO | ||
Thomas Beier, Director | ||
Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
Jon Cohen, Executive Chairman of BioReference Laboratories | ||
Robert Fishel, Independent Director | ||
Robert Baron, Independent Director | ||
Anne Fields, IR Contact Officer | ||
Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
Alice Yu, Independent Director | ||
Steven Rubin, Executive Vice President - Administration, Director | ||
JD Esq, Chief Laboratories | ||
James DeMarco, VP Sales | ||
John Paganelli, Independent Director | ||
Phillip Frost, Chairman of the Board, CEO | ||
Miriam Miller, IR Contact Officer | ||
MBA MBA, Vice Officer | ||
Jon MD, Advisor | ||
Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
Geoff Monk, President of BioReference | ||
Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.19 | |||
Return On Asset | -0.0659 | |||
Profit Margin | (0.26) % | |||
Operating Margin | (0.20) % | |||
Current Valuation | 3.9 B | |||
Shares Outstanding | 772.69 M | |||
Shares Owned By Insiders | 45.87 % | |||
Shares Owned By Institutions | 24.36 % | |||
Price To Book | 0.63 X | |||
Price To Sales | 2.78 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Opko Stock refer to our How to Trade Opko Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |